ANI Pharmaceuticals (ANIP) Ascends While Market Falls: Some Facts to Note
The most recent trading session ended with ANI Pharmaceuticals (ANIP) standing at $56.04, reflecting a +1.12% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily loss of 0.32%. On the other hand, the Dow registered a loss of 0.71%, and the technology-centric Nasdaq decreased by 0.2%.
Heading into today, shares of the drugmaker had lost 2.38% over the past month, lagging the Medical sector's gain of 2.33% and the S&P 500's gain of 4.59% in that time.
Investors will be eagerly watching for the performance of ANI Pharmaceuticals in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.78, indicating a 2.63% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $119.38 million, up 26.69% from the year-ago period.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for ANI Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. ANI Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, ANI Pharmaceuticals is currently exchanging hands at a Forward P/E ratio of 13.65. This indicates a discount in contrast to its industry's Forward P/E of 20.87.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 97, positioning it in the top 39% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
